INOVIQ Exosome Diagnostic Solutions

SubB2M/CA15-3 Test: data and plans Clinical validation study | completed Retrospective, case-control, clinical validation study in 483-samples demonstrated SubB2M/CA15-3 test detected breast cancer across Sall stages with high accuracy (AUC 0.93, 81% sensitivity and 93% ☐ specificity) and outperformed a leading approved CA15-3 test¹ biomarker concentration For personal use only Breast Cancer monitoring study | commenced 2-phase monitoring study in over 200-samples to evaluate performance of SubB2M/CA15-3 test as an aid for monitoring treatment response and/or disease recurrence compared to approved CA15-3 test Data expected Dec-23 SubB2M/CA15-3 and comparator CA15-3 test performance summary Breast Cancer All Stages AUC sensitivity specificity SubB2M Comparator 0.93 0.70 81% 37% 93% 88% false negative rate 19% 63% false positive rate 7% 12% positive predictive value 92% 75% negative predictive value 83% 58% overall accuracy 87% 63% Test Sensitivity by stage @95% Specificity 100% 79% 80% 76% 72% 71% 64% 60% 40% 24% 23% 17% 18% 20% 18% primary treatment recurrence & treatment tumor growth treatment response treatment response 0% Stage I Stage II Stage III Comparator SubB2M Stage IV All Stages 10 1. SubB2M/CA15-3 clinical validation results (ASX: 27/6/23) Breast cancer (n=241: 1=75, II=72, 3=72, III=72, IV = 22) and healthy controls (n=242) INOVIQ

View entire presentation